Edition:
United Kingdom

OvaScience Inc (OVAS.OQ)

OVAS.OQ on NASDAQ Stock Exchange Global Market

0.82USD
14 Aug 2018
Change (% chg)

-- (--)
Prev Close
$0.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
51,705
52-wk High
$1.64
52-wk Low
$0.71

Latest Key Developments (Source: Significant Developments)

OvaScience And Millendo Therapeutics Announce All-Stock Merger
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - OvaScience Inc ::OVASCIENCE AND MILLENDO THERAPEUTICS ANNOUNCE MERGER TO CREATE LEADING RARE ENDOCRINE DISEASE COMPANY.OVASCIENCE INC - CURRENT OVASCIENCE SHAREHOLDERS WILL OWN ABOUT 20% OF COMBINED CO, CURRENT MILLENDO INVESTORS WILL OWN ABOUT 80%.OVASCIENCE INC - TRANSACTION HAS BEEN APPROVED BY BOARD OF DIRECTORS OF BOTH COMPANIES.OVASCIENCE INC - INVESTOR SYNDICATE COMMITTED TO INVEST $30 MILLION IN COMBINED COMPANY.OVASCIENCE - COMBINED CO EXPECTED TO OPERATE UNDER NAME MILLENDO THERAPEUTICS & TRADE ON NASDAQ CAPITAL MARKET UNDER TICKER SYMBOL MLND.OVASCIENCE INC - OVASCIENCE WILL MERGE WITH MILLENDO IN AN ALL-STOCK TRANSACTION.OVASCIENCE INC - TOTAL CASH BALANCE OF COMBINED CO AFTER DEAL CLOSE AND FINANCING EXPECTED TO BE AT LEAST $70 MILLION.  Full Article

Ovascience Says ‍Reducing Headcount By Approximately 50 Percent​
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Ovascience Inc ::OVASCIENCESM ANNOUNCES CORPORATE UPDATE.OVASCIENCE INC - ‍REDUCING HEADCOUNT BY APPROXIMATELY 50 PERCENT​.OVASCIENCE INC - ‍MAJORITY OF REDUCTION IN PERSONNEL IS EXPECTED TO BE COMPLETED BY MARCH 2018​.OVASCIENCE INC - JAMES LILLIE JOINING AS CHIEF SCIENTIFIC OFFICER.OVASCIENCE INC - ‍AS A RESULT OF REDUCTION IN PERSONNEL, CO EXPECTS TO REALIZE ANNUALIZED COST SAVINGS BEGINNING IN Q2 OF 2018​.OVASCIENCE INC - ‍ESTIMATES THAT IT WILL INCUR ONE-TIME COSTS OF APPROXIMATELY $1.0 MILLION TO $1.5 MILLION RELATED TO RESTRUCTURING PLAN​.OVASCIENCE INC - ‍PLANS TO INITIATE A MULTI-CENTER, PROSPECTIVE, CONTROLLED, PHASE 1B/2A CLINICAL TRIAL OF OVAPRIME​.OVASCIENCE INC - ‍EXPECTS TO BEGIN PATIENT ENROLLMENT IN FIRST HALF OF 2018 AND TO REPORT INITIAL CLINICAL DATA IN 2019​ FROM PLANNED OVAPRIME TRIAL.  Full Article

Ovascience reports Q3 loss per share $0.26
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ovascience Inc :Ovascience reports third quarter 2017 financial results.Q3 loss per share $0.26.Q3 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S.Ovascience Inc - ‍expects to incur additional cash outlays related to restructurings of between $1.0 million and $1.5 million over 2017 and 2018​.Ovascience Inc - ‍anticipates that it will have sufficient funds without additional financing to support its operations into q1 of 2020​.  Full Article

Ovascience names Christophe Couturier as CFO
Tuesday, 6 Sep 2016 

Ovascience Inc : Christophe Couturier has been named chief financial officer, effective immediately .Christophe couturier succeeds Jeff Young, who is pursuing other opportunities and will be leaving ovascience after a transition period.  Full Article

BRIEF-Ovascience Reports Q1 Loss Per Share Of $0.21

* OVASCIENCE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE